Chagas disease (CD) is a centenarian neglected parasitosis caused by the protozoan Trypanosoma cruzi (T. cruzi). Despite the continuous efforts of many organizations and institutions, CD is still an important human health problem worldwide. A lack of a safe and affordable treatment has led drug discovery programmes to focus, for years, on the search for molecules enabling interference with enzymes that are essential for T. cruzi survival. In this work, the authors want to offer a brief overview of the different validated targets that are involved in diverse parasite pathways: glycolysis, sterol synthesis, the de novo biosynthesis of pyrimidine nucleotides, the degradative processing of peptides and proteins, oxidative stress damage and purine salvage and nucleotide synthesis and metabolism. Their structural aspects, function, active sites, etc. were studied and considered with the aim of defining molecular bases in the search for new effective treatments for CD. This review also compiles, as much as possible, all the inhibitors reported to date against these T. cruzi targets, serving as a reference for future research in this field.
Keywords: CYP51; Cruzain; Dihydrofolate reductase; Dihydroorotate dehydrogenase; Pteridine reductase; Sterol 14α-demethylase; Superoxide dismutase; Thymidylate synthase; Triosephosphate isomerase; Trypanosoma cruzi; Trypanothione reductase.
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.